Logo image of MENS

JYONG BIOTECH LTD (MENS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MENS - KYG831161065 - Common Stock

3.33 USD
-0.13 (-3.76%)
Last: 1/16/2026, 8:00:01 PM
3.31 USD
-0.02 (-0.6%)
Pre-Market: 1/20/2026, 5:15:37 AM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to MENS. MENS was compared to 525 industry peers in the Biotechnology industry. MENS has a bad profitability rating. Also its financial health evaluation is rather negative. MENS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • MENS had negative earnings in the past year.
  • In the past year MENS has reported a negative cash flow from operations.
MENS Yearly Net Income VS EBIT VS OCF VS FCFMENS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • With a Return On Assets value of -47.42%, MENS perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
Industry RankSector Rank
ROA -47.42%
ROE N/A
ROIC N/A
ROA(3y)-58.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MENS Yearly ROA, ROE, ROICMENS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

  • MENS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MENS Yearly Profit, Operating, Gross MarginsMENS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, MENS has about the same amount of shares outstanding.
  • The debt/assets ratio for MENS is higher compared to a year ago.
MENS Yearly Shares OutstandingMENS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
MENS Yearly Total Debt VS Total AssetsMENS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -7.05, we must say that MENS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -7.05, MENS is not doing good in the industry: 66.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.05
ROIC/WACCN/A
WACCN/A
MENS Yearly LT Debt VS Equity VS FCFMENS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M -30M

2.3 Liquidity

  • A Current Ratio of 0.02 indicates that MENS may have some problems paying its short term obligations.
  • The Current ratio of MENS (0.02) is worse than 95.62% of its industry peers.
  • A Quick Ratio of 0.02 indicates that MENS may have some problems paying its short term obligations.
  • MENS has a Quick ratio of 0.02. This is amonst the worse of the industry: MENS underperforms 95.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
MENS Yearly Current Assets VS Current LiabilitesMENS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

  • MENS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.43%, which is quite impressive.
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MENS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MENS Price Earnings VS Forward Price EarningsMENS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MENS Per share dataMENS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MENS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JYONG BIOTECH LTD

NASDAQ:MENS (1/16/2026, 8:00:01 PM)

Premarket: 3.31 -0.02 (-0.6%)

3.33

-0.13 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-09
Earnings (Next)N/A
Inst Owners0.14%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap253.18M
Revenue(TTM)N/A
Net Income(TTM)-3.02M
AnalystsN/A
Price TargetN/A
Short Float %2.26%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.48
TBVpS-0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -7.05
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.33%
OCF growth 3YN/A
OCF growth 5YN/A

JYONG BIOTECH LTD / MENS FAQ

What is the fundamental rating for MENS stock?

ChartMill assigns a fundamental rating of 0 / 10 to MENS.


What is the valuation status for MENS stock?

ChartMill assigns a valuation rating of 0 / 10 to JYONG BIOTECH LTD (MENS). This can be considered as Overvalued.


What is the profitability of MENS stock?

JYONG BIOTECH LTD (MENS) has a profitability rating of 0 / 10.


How financially healthy is JYONG BIOTECH LTD?

The financial health rating of JYONG BIOTECH LTD (MENS) is 0 / 10.